{
    "clinical_study": {
        "@rank": "154813", 
        "arm_group": {
            "arm_group_label": "Nimotuzumab plus chemoradiotherapy", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Nimotuzumab is a humanized monoclonal antibody against epidermal growth factor receptor\n      (EGFR). Clinical trials are ongoing globally to evaluate Nimotuzumab in different\n      indications. Nimotuzumab has been approved to treat squamous cell carcinoma of head and neck\n      (SCCHN), glioma and nasopharyngeal carcinoma in different countries. The clinical\n      phase\u2161trial is designed to assess the resection rate and pathological complete response of\n      nimotuzumab plus carboplatin and paclitaxel in patients with cervical cancer."
        }, 
        "brief_title": "Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Cervical Cancer", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Cervical Cancer", 
        "condition_browse": {
            "mesh_term": "Uterine Cervical Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age:18-70 years\n\n          2. Histological confirmed Cervical squamous cell carcinoma\n\n          3. FIGO Stage: IB2-IIIB\n\n          4. Tumor lesions and stages are confirmed by the internal medicine, obstetrics and\n             gynecology inspection, including a pelvic exam and abdominal and pelvic CT,.if\n             necessary, laparoscopy, cystoscopy and pelvic MRI examination will be taken.\n\n          5. At least one lesions can be measured\n\n          6. No previous therapy\n\n          7. ECOG performance status 0-2\n\n          8. Life expectancy of more than 6 months\n\n          9. Normal hematology:Haemoglobin\u226590g/L,white blood cell(WBC)\u22654\u00d7109/L Absolute neutrophil\n             count\u22651.5\u00d7109/L,platelet count\u2265100\u00d7109/L, normal renal function: serum\n             creatinine<1.5mg/dl or creatinine clearance rate>60ml/min\uff1bnormal liver\n             function:TBIL\u22641.5 ULN, AST and ALT\u22641.5 ULN\n\n         10. Without lung or heart disease\n\n         11. Without active infection\n\n         12. Signed informed consent and submit to the organization of research\n\n        Exclusion Criteria:\n\n          1. Severe systemic or uncontrolled disease, unfit for chemotherapy\n\n          2. Neuropathy caused by any reason\n\n          3. Psychiatric disease\n\n          4. Other malignant tumor\n\n          5. Bilateral renal pelvis and ureter hydrocephalus who can't be alleviated by ureteral\n             stent or percutaneous nephrostomy, Abnormal serum creatinine level\n\n          6. Infection and severe systemic disease\n\n          7. Received other anti EGFR monoclonal antibody treatment\n\n          8. Participation in other interventional clinical trials\n\n          9. Allergic constitution or history of drug allergy\n\n         10. Pregnant or breast-feeding or refused to take contraceptive method\n\n         11. Poor compliance"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02039791", 
            "org_study_id": "BT-IST-CC-072"
        }, 
        "intervention": [
            {
                "arm_group_label": "Nimotuzumab plus chemoradiotherapy", 
                "description": "200mg/w,weekly, 6 weeks", 
                "intervention_name": "Nimotuzumab", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Nimotuzumab plus chemoradiotherapy", 
                "description": "AUC 6, d1\uff0c1 cycle/21d, 2 cycles", 
                "intervention_name": "Carboplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Nimotuzumab plus chemoradiotherapy", 
                "description": "175 mg/m2, d1\n1 cycle/21d, 2 cycles.", 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Carboplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 16, 2014", 
        "location": {
            "contact": {
                "last_name": "yaping zhu", 
                "phone": "13371989235"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200080"
                }, 
                "name": "Shanghai first people's hospital"
            }, 
            "investigator": {
                "last_name": "yaping zhu", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Cervical Cancer", 
        "overall_contact": {
            "last_name": "yaping zhu", 
            "phone": "13371989235"
        }, 
        "overall_contact_backup": {
            "last_name": "youji Feng", 
            "phone": "13901790541"
        }, 
        "overall_official": {
            "affiliation": "Shanghai First People's Hospital", 
            "last_name": "yaping Zhu", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "China: Food and Drug Administration", 
                "China: Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "resection rate", 
                "safety_issue": "No", 
                "time_frame": "the day right after surgery"
            }, 
            {
                "measure": "Pathological response rate", 
                "safety_issue": "No", 
                "time_frame": "the day right after surgery"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02039791"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "objective response rate\uff08ORR\uff09", 
                "safety_issue": "No", 
                "time_frame": "The first seven weeks after the end of treatment"
            }, 
            {
                "measure": "Progression free survival  progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Follow-up is for three consecutive years after surgery. Once every three months in the first year, and then once every six months in the second and third year."
            }
        ], 
        "source": "Biotech Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biotech Pharmaceutical Co., Ltd.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}